title: IL-1 and IL-1 inhibitory activity in the culture supernatants of alveolar macrophages from patients with interstitial lung diseases.
abstract: Under normal conditions, the release of interleukin 1 (IL-1) and IL-1 inhibitors play a role in tissue homeostasis. We have already reported an increase in IL-1 activity and a decrease in IL-1 inhibitory activity (IHA) in the supernatants of alveolar macrophages from healthy long-term smokers as compared with healthy nonsmokers. In this study, we report an alteration in the release of IL-1 and IL-1 IHA from alveolar macrophages in patients with interstitial lung diseases (sarcoidosis and idiopathic pulmonary fibrosis [IPF]). IL-1 activity released from alveolar macrophages stimulated by lipopolysaccharide was increased in patients with active sarcoidosis (mean +/- SD, 2.52 +/- 1.33 U/ml [n = 6] vs 1.38 +/- 0.62 U/ml [n = 15] for healthy non-current smokers [HNS]; p less than 0.05). IL-1 IHA released from alveolar macrophages was significantly different among the groups examined: a decrease of IL-1 IHA occurred in patients with active sarcoidosis (61.4 +/- 19.2 [n = 6] vs 85.9 +/- 13.9 percent:HNS; p less than 0.05) and IPF (64.7 +/- 18.5 [n = 9]; p less than 0.05). Prednisolone in the culture medium at physiologic concentrations suppressed the release of IL-1 and enhanced the release of IL-1 IHA. IL-1 IHA inhibited not only mouse thymocyte proliferation but also human fibroblast proliferation in the presence of IL-1.
authors.affiliation: Second Department of Medicine, Kyoto University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nagai
authors.forename: H
authors.initials: H
authors.lastname: Aung
authors.forename: M
authors.initials: M
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Kusume
authors.forename: T
authors.initials: T
authors.lastname: Izumi
mesh_terms: D000328:Adult; D001992:Bronchoalveolar Lavage Fluid / Q000473:pathology; D005260:Female; D005347:Fibroblasts / Q000473:pathology; D006131:Growth Inhibitors / Q000032:analysis*; D006801:Humans; D007375:Interleukin-1 / Q000032:analysis* / Q000037:antagonists & inhibitors; D008055:Lipids / Q000032:analysis*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008171:Lung Diseases / Q000473:pathology*; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000032:analysis*; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011650:Pulmonary Alveoli / Q000473:pathology*; D011658:Pulmonary Fibrosis / Q000473:pathology*; D012507:Sarcoidosis / Q000473:pathology*; D012907:Smoking / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D006131:Growth Inhibitors; D007375:Interleukin-1; D008055:Lipids; D008070:Lipopolysaccharides; D008222:Lymphokines